Dr. Anna Nikolaidou | Nanomedicine | Best Researcher Award

Dr. Anna Nikolaidou | Nanomedicine | Best Researcher Award

Dr. Anna Nikolaidou, National and Kapodistrian University of Athens, Greece

Dr. Anna Nikolaidou 🩺✨ is a Greek ophthalmologist and researcher specializing in nanomedicine and retinal diseases. Currently a Myopia Research Fellow in Tübingen, Germany 🇩🇪, she explores the visual impact of removing chromatic aberration in emmetropes and myopes. With an MD from Aristotle University of Thessaloniki (graduated with honors 🎓), she holds two MSc degrees focusing on medical research methodology and nanomedicine. Dr. Nikolaidou has published in renowned journals, combining artificial intelligence 🤖 and teleophthalmology 📡 to advance retinal disease diagnosis. Her innovative work bridges cutting-edge science and patient care 🌟, making her a rising leader in ophthalmology.

Professional  Profile:

Scopus

Orcid

Suitability Summary

Dr. Anna Nikolaidou is an exemplary candidate for the Best Researcher Award due to her outstanding contributions to ophthalmology, nanomedicine, and retinal disease research. Her pioneering work bridges cutting-edge science, such as nanotechnology and artificial intelligence (AI), with clinical practice, advancing diagnosis, treatment, and care for complex eye conditions. With multiple academic achievements, prestigious research fellowships, and innovative projects in AI-based retinal disease diagnosis and nanomedicine, Dr. Nikolaidou has demonstrated leadership, innovation, and impact in her field.

Education and Experience

  • 🎓 MSc in Nanomedicine (2023 – Ongoing)
    Thesis: Utilization of Nanoparticles for Treating Age-related Macular Degeneration.
  • 🎓 MSc in Medical Research Methodology (2021 – 2023)
    Thesis: AI Algorithms for Retinopathy of Prematurity Diagnosis.
  • 🎓 Doctor of Medicine (MD) (2015 – 2021)
    Aristotle University of Thessaloniki – Graduated Excellent (9.47/10).
  • 🩺 Myopia Research Fellow (2024 – Present)
    Institute of Ophthalmic Research, Tübingen, Germany.
  • 👁️ Ophthalmology Resident (2023 – 2024)
    Aghia Sophia Children’s Hospital, Greece.
  • 🔬 Research Fellow (2022 – 2023)
    LIFE4LV Project (ClinicalTrials.gov Identifier: NCT05184036).

Professional Development

Dr. Nikolaidou’s career integrates innovation and research 🌐. She has contributed to AI-based retinal disease diagnosis 🤖 and teleophthalmology 📡, enhancing ophthalmic care post-COVID-19. At Moorfields Eye Hospital, she studied medical retina and genetics 🔬. Her award-winning work includes systematic reviews on glaucoma management and space medicine. Through conference presentations 🎤 at prestigious platforms, including the American Academy of Ophthalmology 🇺🇸, and publications in high-impact journals 📚, she continues to shape the future of eye care. Dr. Nikolaidou’s passion for nanotechnology and theranostics demonstrates her commitment to blending science and clinical practice for global health 🌍.

Research Focus

Dr. Nikolaidou focuses on nanomedicine 🧬, applying nanoparticles for retinal disease treatment. Her research delves into AI algorithms 🤖 for diagnosis, particularly retinopathy of prematurity and space medicine 🚀. At the forefront of ophthalmology, she examines the removal of chromatic aberration for better visual outcomes 👁️. Her innovative projects emphasize theranostics 🩻, integrating diagnostics and treatment. Through interdisciplinary collaboration 🌐, she contributes to advancing retinal care, leveraging teleophthalmology 📡 and cutting-edge imaging technologies 🖥️. With a commitment to addressing complex eye conditions, her work aims to improve diagnosis, management, and patient outcomes globally 🌍.

Awards and Honors

  • 🏆 Presented research at the American Academy of Ophthalmology and European Pediatric Ophthalmology Congress.
  • 🥇 Recognized for innovative AI-based research on retinal diseases and space medicine.
  • 🏅 Published impactful studies in prestigious journals like Journal of Glaucoma and Brain & Development.
  • 🌟 Honored for contributions to teleophthalmology and post-COVID ophthalmic care strategies.

Publication Top Notes:

  • Virtual Reality With Eye Tracking for Pediatric Ophthalmology: A Systematic Review
  • 📄 The Effect of Phacoemulsification on the Intraocular Pressure of Patients With Open Angle Glaucoma: A Systematic Review and Meta-Analysis

    🔗 2 Citations

  • 📄 Neuropsychiatric manifestations associated with Juvenile Systemic Lupus Erythematosus: An overview focusing on early diagnosis

    🔗 2 Citations

  • 📄 Investigation of Sleep Quality and Mental Health of Greek Physicians During the COVID-19 Pandemic
  • 📄 Microgravity induced resting state networks and metabolic alterations during sleep onset

    🔗 1 Citation

 

Ms. Moloud Farrokhi | Nanodelivery Awards | Best Researcher Award

Ms. Moloud Farrokhi | Nanodelivery Awards | Best Researcher Award

Ms. Moloud Farrokhi , Albany Medical college, United States

Mouloud Farrokhi is an experienced immunologist and microbiologist specializing in HIV/AIDS research, nanoparticle delivery systems, and viral infections. He is currently pursuing a PhD in Biology with a focus on Immunology and Microbiology at Albany Medical College, USA. Mouloud has a strong academic and professional background, having worked as a research assistant and medical laboratory scientist in Iran and Sweden. His research aims to improve understanding and treatment of viral infections, with significant contributions to HIV drug resistance and oncolytic virus therapy. Mouloud’s work also extends to the development of innovative nanoparticle-based drug delivery systems, offering promising solutions for invasive infections like Aspergillosis. His expertise spans from molecular biology to clinical research, with an emphasis on laboratory techniques like PCR, qRT-PCR, NGS, and CRISPR/Cas9.

Professional Profile:

Google Scholar

Mouloud Farrokhi: A Strong Contender for the Research Best Researcher Award

Mouloud Farrokhi is an exceptional candidate for the Research Best Researcher Award due to his extensive background in immunology, microbiology, and viral infections, as well as his significant contributions to molecular diagnostics and therapeutic innovations. His educational qualifications, research experience, and recognition in the field of medical sciences make him a highly suitable candidate for this prestigious award.

🎓Education:

Mouloud Farrokhi is currently pursuing a PhD in Biology, specializing in Immunology and Microbiology at Albany Medical College, USA (2023–Present). He holds two Master’s degrees: an MSc in Bioscience from the University of Skövde, Sweden (2021–2022), with a thesis on the role of RABL6 in AP3-dependent trafficking, and an MSc in Cellular and Molecular Biology from the Islamic Azad University, Iran (2010–2014), where he researched HIV-1 drug resistance. His undergraduate studies were in Marine Biology at the Islamic Azad University, Tehran, Iran (2003–2008). Mouloud’s extensive education in biological sciences provides a solid foundation for his current research endeavors, focusing on viral infections, molecular diagnostics, and therapeutic innovations.

🏢Experience:

Mouloud Farrokhi has gained extensive experience as a research assistant and medical laboratory scientist. He worked as a Research Assistant at Tehran University of Medical Sciences (2022–2023), where he focused on statistical analysis and NGS (Next Generation Sequencing). He has also served as a Medical Laboratory Assistant at Tehran University of Medical Sciences (2018–2021), where he conducted HIV viral load analysis and COVID-19 testing via qPCR. His previous roles include being a Medical Laboratory Scientist at Dena Lab (2017–2018), where he performed NITP tests and a Research Assistant at Pasteur Institute of Iran (2016–2017), where he researched drug resistance in HIV and HCV. He has also contributed to laboratory work at Keyvan Virology Laboratory, Tehran (2015–2016). Mouloud’s diverse hands-on experience makes him proficient in molecular biology techniques, data analysis, and lab management.

🏅Awards and Honors:

Mouloud Farrokhi’s academic and research achievements are reflected in his high academic standing and contributions to scientific research. His thesis at the University of Skövde received top marks, with a GPA of 3.75, and he has consistently demonstrated excellence throughout his academic career. His research contributions have been recognized in various publications and presentations. Notably, he presented at the International Student Congress in Medical Sciences (ISCOM) in 2017 and at the Upstate New York Immunology Conference (NYIC) in 2024. Mouloud’s work in HIV drug resistance and nanoparticle drug delivery systems has been published in high-impact journals. His dedication to advancing medical science has led to multiple research opportunities, including participation in workshops on gene transfer and vaccine design.

🔬Research Focus:

Mouloud Farrokhi’s research focuses on immunology, microbiology, and the molecular mechanisms underlying viral infections and drug resistance. He investigates the molecular pathways of HIV and other viral infections, focusing on drug resistance mechanisms in HIV-1 and HCV. His research also explores innovative strategies for oncolytic virus therapy and nanoparticle-based drug delivery, with the goal of improving treatment outcomes for invasive infections like Aspergillosis. Additionally, he is involved in genetic analysis and genomic editing technologies such as CRISPR/Cas9. Mouloud’s work integrates molecular diagnostics and therapeutic advancements, contributing significantly to both basic science and clinical applications in virology and immunology.

Publication Top Notes:

  • “Subtype classification of Iranian HIV-1 sequences registered in the HIV databases, 2006-2013”
    • Citations: 31
  • “HIV drug resistance among naïve HIV-infected patients in Iran”
    • Citations: 14
  • “Antiretroviral drug resistance mutations among HIV treatment failure patients in Tehran, Iran”
    • Citations: 11
  • “The first characterization of HIV-1 subtypes and drug resistance mutations among antiretrovirally treated patients in Kermanshah, Iran”
    • Citations: 9
  • “HIV drug resistance and phylogeny profile in naive and antiretroviral-experienced patients in Tehran, Iran”
    • Citations: 8

 

 

 

Dr. Angela Fabiano | Pharmaceutics Awards | Best Researcher Award

Dr. Angela Fabiano | Pharmaceutics Awards | Best Researcher Award

Dr. Angela Fabiano,University of Pisa,Italy

Angela Fabiano is a senior researcher at the University of Pisa, Department of Pharmacy, specializing in drug delivery systems. She earned her Ph.D. in Science of Drugs and Bioactive Substances in 2016, with a focus on innovative pharmaceutical systems based on chitosan and its derivatives. Her research involves the synthesis, purification, and characterization of chitosan derivatives to enhance solubility and pharmaceutical applications, including nanosystems and hydrogels for drug delivery via ocular and oral routes. In 2020, she achieved the scientific qualification for associate professor and has authored over 30 publications, with around 800 citations.

Professional Profile:

Orcid

Scopus

Suitability for Best Researcher Award:

Angela Fabiano’s innovative research in drug delivery systems, significant academic contributions, and recognized scientific qualifications make her an outstanding candidate for the Best Researcher Award. Her work directly impacts the development of novel pharmaceutical systems, positioning her as a leader in her field.

🎓Education:

Angela Fabiano earned her Ph.D. in Science of Drugs and Bioactive Substances from the University of Pisa in 2016. Her doctoral thesis, titled “Innovative Pharmaceutical Systems Based on Chitosan and Its Derivatives,” focused on developing novel pharmaceutical systems using chitosan and its derivatives. Her research explored the synthesis, purification, and characterization of these derivatives to improve solubility and expand their pharmaceutical applications, particularly in the creation of advanced drug delivery systems. This work laid the foundation for her continued contributions to drug delivery research.

🏢Work Experience:

Angela Fabiano is currently a Senior Researcher at the Department of Pharmacy, University of Pisa. Her research focuses on drug delivery systems, specifically the synthesis, purification, and characterization of chitosan derivatives. She is dedicated to advancing the development of nanosystems and hydrogels for drug delivery through various routes, including ocular and oral. Her work aims to enhance the effectiveness and versatility of pharmaceutical applications, contributing significantly to the field of drug delivery.

🏅Awards & Achievements:

Angela Fabiano is currently a Senior Researcher at the Department of Pharmacy, University of Pisa. Her research focuses on drug delivery systems, including the synthesis, purification, and characterization of chitosan derivatives. She is also involved in the development of advanced nanosystems and hydrogels for drug delivery through ocular and oral routes. In 2020, she achieved scientific qualification for the role of Associate Professor at the University of Pisa. She has authored over 30 publications in journals with medium to high impact factors, and her work has been cited approximately 800 times, underscoring her significant contributions to the field.

Publication Top Notes:

  • Title: Cross-Linked Thiolated Hydroxypropyl-β-Cyclodextrin for Pulmonary Drug Delivery
  • Title: Olive Leaf Extracts from Three Italian Olive Cultivars Exposed to Drought Stress Differentially Protect Cells against Oxidative Stress
  • Title: Betaine- and L-Carnitine-Based Ionic Liquids as Solubilising and Stabilising Agents for the Formulation of Antimicrobial Eye Drops Containing Diacerein
  • Title: Bergamot Essential Oil: A Method for Introducing It in Solid Dosage Forms
  • Title: Thiolated Hydroxypropyl-β-Cyclodextrin: A Potential Multifunctional Excipient for Ocular Drug Delivery